Aug 21, 2022 - Health

FDA authorizes Novavax vaccine for ages 12 to 17

Novavax
Photo: Justin Tallis/AFP via Getty Images

The Food and Drug Administration has authorized Novavax's COVID-19 vaccine for emergency use for adolescents between the ages of 12 and 17, the biotech company announced Friday.

Why it matters: The news could be a boon for unvaccinated people who prefer a shot that is not based on the mRNA technology used by Pfizer and Moderna.

What they're saying: The development "will hopefully help increase vaccination rates, particularly as we prepare for ongoing surges of COVID-19 with the start of fall and the back-to-school season," said Novavax president and CEO Stanley Erck in a statement.

  • "We hope that our vaccine, developed using an innovative approach to recombinant protein vaccine technology, may have a special role in adolescent vaccination based on parents' and caregivers' familiarity with protein-based vaccines used in other disease areas."

Catch up quick: Novavax won $1.6 billion in federal backing in 2020 as part of Operation Warp Speed. The company's two-dose vaccine was granted emergency authorization from the FDA for use in adults in July.

Go deeper